KalVista Reports $49.1M EKTERLY Revenue, Early Pediatric Trial Completion, and Funding Through Profitability
Summary
KalVista Pharmaceuticals reported strong financial results for the eight months ended December 31, 2025, recognizing $49.1 million in global net product revenue for EKTERLY. The company highlighted robust commercial progress, with 1,702 patient start forms received in the US, representing nearly 20% of the patient population, and successful launches in Germany and Japan. Critically, KalVista completed enrollment in its Phase 3 KONFIDENT-KID trial for pediatric HAE a full year ahead of schedule and expects to file a US new drug application in Q3 2026. With approximately $300.2 million in cash, cash equivalents, and marketable securities, the company anticipates being funded through profitability, a significant positive indicator for investors. This comprehensive update signals strong commercial traction, accelerated clinical development, and a solid financial position, which are key drivers for the stock. Investors will be watching for the interim analysis data presentation later this month and the pediatric NDA filing.
At the time of this announcement, KALV was trading at $16.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $832M. The 52-week trading range was $9.24 to $19.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.